XOMA Royalty Corp.
NASDAQ:XOMABiotechnology
+$0.19 today
- Market cap
- $503.77M
- Beta
- 0.87
- P/E (TTM)
- 15.8
- EPS (TTM)
- $2.65
Volume 4.22M
Average 0.21M
XOMA Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
XOMA Royalty Corp.NASDAQ: XOMA
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 2392.6% from a year ago
Other current liabilities stood at $10.82M at the end of Q1 FY2026, up 2392.6% from a year earlier and up 9.4% from the prior quarter. Over 3 fiscal years it compounded at +61.4% a year.
Context
- Other current liabilities amounted to 4.0% of total assets at the end of Q1 FY2026, up 3.8 pp from a year earlier.
- Other current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +2392.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 9.89M USD
- Year-over-year change
- +229.6%
- 4-year CAGR
- +5.0%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.89M | +229.6% |
| FY2024 | 2024-12-31 | 3M | -69.3% |
| FY2023 | 2023-12-31 | 9.78M | +316.3% |
| FY2022 | 2022-12-31 | 2.35M | -71.1% |
| FY2021 | 2021-12-31 | 8.13M | — |
Other Current Liabilities vs competitors
How XOMA compares with its peers on the latest reported figures
- XOMA's Mar 2026 other current liabilities of $10.82M is the 3rd highest of the 10 companies compared; the peer median is $2.33M.
- Its year-over-year change of +2392.6% is the highest of 10, against a peer median of +27.0%.
- Other current liabilities amounts to 4.0% of total assets for XOMA, versus a peer median of 1.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $39.96M | +71.0% | +74.1% | 7.6% | |
| Mar 2026 | $18.15M | +122.3% | +49.7% | 4.3% | |
| Mar 2026 | $10.82M | +2392.6% | +61.4% | 4.0% | |
| Mar 2026 | $5.24M | +26.8% | +7.1% | 1.8% | |
| Mar 2026 | $2.97M | -6.6% | +27.3% | 2.2% | |
| Mar 2026 | $2.33M | +22.9% | +9.3% | 1.0% | |
| Mar 2026 | $1.37M | +698.3% | — | 0.6% | |
| Mar 2026 | $741K | +117.3% | +27.4% | 1.4% | |
| Mar 2026 | $545K | -36.0% | -49.3% | 3.5% | |
| Mar 2026 | $541K | +27.0% | +2.1% | 0.3% | |
| Peer median (excluding XOMA) | $2.33M | +27.0% | +18.3% | 1.8% | |
Competitors are the stored peer set for XOMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 93.33M | 57.83M | 153.29M | 101.65M | 82.91M |
| Short-term Investments | 774K | 335K | 161K | 3.53M | 382K |
| Net Receivables | 209K | 2.37M | 15.22M | 17.02M | 4.9M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 2.05M | 725K | 643K | 1.33M | 29.46M |
| Total Current Assets | 96.97M | 61.25M | 169.31M | 125.6M | 117.26M |
| Property, Plant & Equipment (Net) | 213K | 36K | 403K | 351K | 277K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 15.15M | 0 | 25.91M | 44.76M |
| Long-term Investments | 0 | 63.68M | 64.05M | 64.34M | 106.38M |
| Tax Assets | 0 | (63.68M) | 0 | 0 | 0 |
| Other Non-current Assets | 69.38M | 63.94M | 533K | 5.08M | 4.03M |
| Total Non-current Assets | 69.59M | 79.13M | 64.99M | 95.67M | 155.44M |
| Total Assets | 166.56M | 140.38M | 234.3M | 221.28M | 272.7M |
| Account Payables | 1.07M | 524K | 653K | 1.05M | 2.21M |
| Short-term Debt | 0 | 0 | 5.54M | 11.39M | 12.53M |
| Tax Payables | 91K | 0 | 0 | 280K | 0 |
| Deferred Revenue | 1.64M | 1.9M | 2.11M | 1.36M | 1.27M |
| Other Current Liabilities | 8.13M | 2.35M | 9.78M | 3M | 9.89M |
| Total Current Liabilities | 12.97M | 6.82M | 19.5M | 24.37M | 34.82M |
| Long-term Debt | 0 | 0 | 118.52M | 106.88M | 116.57M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 103K |
| Deferred Revenue (Non-current) | 11.69M | 9.55M | 7.23M | 4.41M | 3.19M |
| Other Non-current Liabilities | 0 | 0 | 0 | 3.21M | 14.06M |
| Total Non-current Liabilities | 11.72M | 9.55M | 126.08M | 114.98M | 133.92M |
| Total Liabilities | 24.69M | 16.37M | 145.58M | 139.36M | 168.74M |
| Common Stock | 85K | 86K | 86K | 90K | 89K |
| Retained Earnings | (1.17B) | (1.18B) | (1.22B) | (1.24B) | (1.22B) |
| Accumulated OCI | 0 | 0 | 0 | 73K | 53K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 141.88M | 124.01M | 88.72M | 81.92M | 103.96M |
| Total Debt | 229K | 34K | 124.45M | 119.2M | 131.56M |
| Net Debt | (93.1M) | (57.79M) | (28.84M) | 17.54M | 48.65M |
XOMA Royalty Corp.
NASDAQ:XOMA
Intrinsic Alpha fair value
Locked
Current Price
$40.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.